ATMI and Sartorius Stedim Biotech Extend Global Supply and Marketing Alliance
ATMI, Inc. (Danbury, CT), and Sartorius Stedim Biotech S.A. (Aubagne, France) have extended their marketing and distribution alliance by adding new technologies.
ATMI, Inc. (Danbury, CT), and Sartorius Stedim Biotech S.A. (Aubagne, France) have extended their marketing and distribution alliance by adding new technologies. The new agreement grants global marketing and distribution rights to ATMI's patented Magnetic Mixer technology to Sartorius. ATMI's Magnetic Mixer is a mobile, mixing system designed for mixing applications in various volumes. It is used in biopharmaceutical processes that require powerful mixing torque, such as buffer and media preparation, and final product formulation applications.
Under the extended agreement, Sartorius retains continued distribution and marketing rights to ATMI LifeSciences' LevMixer mixing system technology that Sartorius has been marketing since April 2008. The LevMixer system is a single-use mixing system that uses patented technology to levitate and drive a single-use impeller inside sterile bags. It mainly is used for liquid-to-liquid applications in downstream purification and sensitive formulation steps, as well as easy-to-dissolve powders, such as salts and buffers.
The expanded agreement also grants Sartorius rights to ATMI's portfolio of bioreactor-related intellectual property, which allows Sartorius to further enable its line of BIOSTAT CultiBag STR single-use bioreactors.
The supply and marketing agreement is a five-year global agreement containing an additional five-year continuity-of-supply clause.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
